Showing results (241-250 of 442) with videos related to
Sort By:
Pageof 45
Inflammatory Bowel Diseases|April 3, 2014
Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cellsAito Ueno, Humberto Jijon, Suzanne Traves, et al.BMJ Open Gastroenterology|September 1, 2025
Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programmeMaría Chaparro, Remo Panaccione, Bruce E Sands, et al.Journal of Crohn'S & Colitis|September 20, 2022
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical ProgrammeWilliam J Sandborn, Geert R D'Haens, Bruce E Sands, et al.Gastro Hep Advances|April 7, 2025
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's DiseaseBrian G Feagan, Remo Panaccione, Stefan Schreiber, et al.Crohn'S & Colitis 360|May 14, 2025
US and European Patient and Health Care Professional Perspectives on Fatigue in Ulcerative Colitis and Crohn's Disease: Results From the Communicating Needs and Features of Inflammatory Bowel Disease Experiences SurveyRemo Panaccione, Alison Potts Bleakman, Stefan Schreiber, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 9, 2024
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced TherapiesBruce E Sands, Geert D'Haens, Remo Panaccione, et al.The American Journal of Gastroenterology|August 27, 2014
Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3Jean-Frederic Colombel, William J Sandborn, Subrata Ghosh, et al.Journal of Crohn'S & Colitis|April 1, 2025
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitisWalter Reinisch, Edward V Loftus, Stefan Schreiber, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisStephen Hanauer, Remo Panaccione, Silvio Danese, et al.Crohn'S & Colitis 360|March 31, 2023
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysisRemo Panaccione, Eric B Collins, Gil Y Melmed, et al.Pageof 45